About: Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach
Creator	Behbahani, Mandana Mohabatkar, Hassan Nosrati, Mokhtar
Source	Elsevier; Medline; PMC
abstract	Crimean-Congo hemorrhagic fever (CCHF) is considered one of the major public health concerns with case fatality rates of up to 80%. Currently, there is no effective approved vaccine for CCHF. In this study, we used a computer-aided vaccine design approach to develop the first multi-epitope recombinant vaccine for CCHF. For this purpose, linear B-cell and T-cell binding epitopes from two structural glycoproteins of CCHF virus including Gc and Gn were predicted. The epitopes were further studied regarding their antigenicity, allergenicity, hydrophobicity, stability, toxicity and population coverage. A total number of seven epitopes including five T-cell and two B-cell epitopes were screened for the final vaccine construct. Final vaccine construct composed of 382 amino acid residues which were organized in four domains including linear B-cell, T-cell epitopes and cholera toxin B-subunit (CTxB) along with heat labile enterotoxin IIc B subunit (LT-IIc) as adjuvants. All the segments were joined using appropriate linkers. The physicochemical properties as well as the presence of IFN-γ inducing epitopes in the proposed vaccine, was also checked to determining the vaccine stability, solubility and its ability to induce cell-mediated immune responses. The 3D structure of proposed vaccine was subjected to the prediction of computational B-cell epitopes and molecular docking studies with MHC-I and II molecules. Furthermore, molecular dynamics stimulations were performed to study the vaccine-MHCs complexes stability during stimulation time. The results suggest that our proposed vaccine was stable, well soluble in water and potentially antigenic. Results also demonstrated that the vaccine can induce both humoral and cell-mediated immune responses and could serve as a promising anti-CCHF vaccine candidate.
has issue date	2019-03-27(xsd:dateTime)
bibo:doi	10.1016/j.jbi.2019.103160
bibo:pmid	30928513
has license	no-cc
sha1sum (hex)	4ec02c71e62b4df8efeed2f53623778f49c7438a
schema:url	https://doi.org/10.1016/j.jbi.2019.103160
resource representing a document's title	Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach
has PubMed Central identifier	PMC7106074
has PubMed identifier	30928513
schema:publication	J Biomed Inform
resource representing a document's body	covid:4ec02c71e62b4df8efeed2f53623778f49c7438a#body_text
is schema:about of	named entity 'COMPUTER' named entity 'APPROACH' named entity 'RECOMBINANT VACCINE' named entity 'EPITOPE' named entity 'VACCINE DESIGN' named entity 'MULTI' named entity 'CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS' named entity 'R T' covid:arg/4ec02c71e62b4df8efeed2f53623778f49c7438a named entity 'virus' named entity 'epitope' named entity 'vaccine design' named entity 'toll-like receptors' named entity 'W109' named entity 'vaccine' named entity 'good manufacturing practice' named entity 'epitope' named entity 'solvation' named entity 'B-cell' named entity 'TLRs' named entity 'CCHFV' named entity 'NCBI' named entity 'PDB' named entity 'viral infections' named entity 'B-cell' named entity 'epitope mapping' named entity 'Leishmania infantum' named entity 'MHC' named entity 'secondary structure' named entity 'protein structure' named entity 'vaccine design' named entity 'vaccine' named entity 'vaccine' named entity 'A352' named entity 'protein' named entity 'immunogenicity' named entity 'A116' named entity 'vaccine' named entity 'epitope' named entity 'CCHFV' named entity 'supportive care' named entity 'amino acid' named entity 'antigenicity' named entity 'expression vector' named entity 'B-cell' named entity 'adjuvants' named entity 'CCHFV' named entity 'nucleoprotein' named entity 'MHC-I' named entity 'epitopes' named entity 'epitopes' named entity 'bacteria' named entity '3D structure' named entity 'quality factor' named entity 'restriction sites' named entity 'vaccine' named entity 'F188' named entity 'epitope' named entity 'alpha helix' named entity 'immunogenicity' named entity 'pred' named entity 'molecular docking' named entity '3D structure' named entity 'MHC-I' named entity 'cloning' named entity 'epitope' named entity 'CCHFV' named entity 'infectious disease' named entity 'allergenicity' named entity 'protein' named entity 'CD8 +' named entity 'binding affinity' named entity 'K102' named entity 'adjuvants' named entity 'antigens' named entity 'epitope' named entity 'molecular docking' named entity 'Escherichia coli K12' named entity 'protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software